Log in to search using one of your social media accounts:

 

Leukemic mesenchymal stromal cell COX2-PG signaling regulates donor anti-leukemia immunity

Hematopoietic stem cell transplantation (HSCT) is considered the gold standard for treatment of hematologic malignancies, including Fanconi anemia (FA), a cancer-prone disease with extremely high incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, eradication of residual leukemia stem cells (LSCs), which often contributes to relapse, remains the challenge for HSCT. Here we investigate the interaction between leukemic mesenchymal niche and donor hematopoietic stem progenitor cells (HSPCs) by modeling FA HSCT.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research

Related Links:

A Boston biotech with a unique approach to treating an aggressive brain tumor, Ziopharm Oncology reported this weekend that its combination of experimental drugs has helped 15 patients survive about twice as long as they would have otherwise in an early-stage trial. Ziopharm (Nasdaq: ZIOP) reported the updated trial data in patients with recurrent glioblastoma at the Society for Neuro-Oncology this weekend. The 15 patients are all being treated with Ziopharm’s gene therapy, called Ad-RTS-hIL-12,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Beneš P, Ranc V, Konvalinka J, Zbořil R Abstract Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a ...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
AN UNCOMMON cancer in the UK could be causing your sore throat or tiredness.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ZURICH (Reuters) - Roche announced two trial wins for its cancer and hemophilia drugs on Monday, boosting its shares and weighing on the stocks of its main rivals.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
We appreciate the comments on our article “Predictive value of neutrophil-to-lymphocyte ratio in diabetic wound healing.”1 There is an increasing body of evidence for predictability of neutrophil-to-lymphocyte ratio (NLR) for outcomes in different diseases, including cancers and cardiovascular diseases.2,3 We appreciate the attention to our findings, and address the raised concerns as follows.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Tags: Letter to the Editor Source Type: research
Researchers point to a large incidence of post-traumatic stress disorder cases at 6 months after a cancer diagnosis and urge better mental health support.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Mental Health Source Type: news
[Daily News] THE much awaited National Cancer Treatment Guidelines, which are envisioned to assist the government have proper forecast of cancer medicines and other services, are in their final stages.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
ZURICH (Reuters) - Roche announced a double dose of trial wins on Monday, saying its immunotherapy Tecentriq mixed with other drugs made advances against lung cancer, while data suggested its haemophilia agent Hemlibra could be used by more patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Young Son M, Deng CX, Hoeijmarkers JH, Rebel VI, Hasty P Abstract Benzene is a common environmental toxin and its metabolite, 1-4-Benzoquinone (BQ) causes hematopoietic cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). BQ has not been comprehensively assessed for its impact on genome maintenance, limiting our understanding of the true health risks associated with benzene exposure and our ability to identify people with increased sensitivity to this genotoxin. Here we analyze the impact BQ exposure has on wild type and DNA repair-defective mouse embryonic stem (ES) cells and wild...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: September–December 2014 Source:Best Practice & Research Clinical Haematology, Volume 27, Issues 3–4 Author(s): Blanche P. Alter Fanconi anemia (FA) is a rare autosomal recessive cancer-prone inherited bone marrow failure syndrome, due to mutations in 16 genes, whose protein products collaborate in a DNA repair pathway. The major complications are aplastic anemia, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and specific solid tumors. A severe subset, due to mutations in FANCD1/BRCA2, has a cumulative incidence of cancer of 97% by age 7 years; the cancers are AML, brain ...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Cancer | Cancer & Oncology | Faconi Anemia | Hematology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants